Day: January 6, 2021

Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer  6 January 2021LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the appointment of Craig Tooman as the Company’s Chief Financial Officer (CFO) and member of the Executive Leadership Team, effective immediately.Mr. Tooman has a successful career in the biopharmaceutical industry spanning more than 30 years, including 15 years of experience as a public company CFO. Most recently, he was CFO and COO at Vyome Therapeutics, and prior to this was CFO and then CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco....

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m. ET.Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.About BioCryst PharmaceuticalsBioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adults and pediatric patients...

AUSTIN, Texas, Jan. 06, 2021 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading provider of professional testing, inspection, environmental, engineering, program management and consulting services, announced today that it was awarded a 3-year contract, valued at $2.6 million for special inspection and materials testing for the proposed University of California San Diego (UCSD) Theatre District Living and Learning Neighborhood.Previously known as the Future College Living and Learning Neighborhood project, the Theatre District Living and Learning Neighborhood is a mixed-use project that would include five buildings ranging in height from nine to 21 stories and provide approximately 2,000 new beds for undergraduate students, residential life and administration offices for a new...

VANCOUVER, British Columbia, Jan. 06, 2021 (GLOBE NEWSWIRE) — Corvus Gold Inc. (“Corvus” or the “Company”) – (TSX: KOR, NASDAQ: KOR) announces it has received results from the second hole into the new Northern High-Grade Feeder Zone target of the Central Intrusive Zone (CIZ).  Hole ML20-165CT drilled into the CIZ returning 130.5m @ 2.33 g/t gold including 27.7m @ 4.46 g/t gold & 9.26 g/t silver.  This new high-grade feeder zone is showing good continuity and Corvus believes it could expand the grade and size of the Mother Lode gold system in the northern end of the deposit.  Like earlier results from this area (hole ML20-159CT with 83.9m @ 2.7 g/t gold including 12.7m @ 8.5 g/t gold and 30.4 g/t silver, see NR20-18, November 12. 2020), the mineralization appears to be associated with the lower intrusives dike/breccia...

MONTREAL, Jan. 06, 2021 (GLOBE NEWSWIRE) — Goodfood Market Corp. (“Goodfood” or “the Company”) (TSX: FOOD), a leading online grocery company in Canada, will release its financial results for the first quarter of Fiscal 2021 on Wednesday, January 13, 2021, before markets open. Jonathan Ferrari, CEO, Neil Cuggy, President and COO, and Philippe Adam, CFO, will hold a conference call to review the results at 8:00 a.m. (ET) on the same day. In addition, Goodfood’s Annual General Meeting of Shareholders will also be held on Wednesday, January 13, 2021 at 10:00 a.m. (ET). The meeting will be held virtually through the platform Lumi.Details of the Q1 Earnings Conference Call:When: January 13, 2021 at 8:00 a.m. ETDial in number: 1-877-223-4471 or 1-647-788-4922Conference call replay available until January 20, 2021:1-800-585-8367 or 1-416-621-4642To...

MONTRÉAL, 06 janv. 2021 (GLOBE NEWSWIRE) — Marché Goodfood Corp. (« Goodfood » ou la « Société ») (TSX : FOOD), un chef de file canadien de l’épicerie en ligne, publiera ses résultats financiers pour le premier trimestre de l’exercice financier 2021 le mercredi 13 janvier 2021, avant l’ouverture des marchés financiers. Jonathan Ferrari, chef de la direction, Neil Cuggy, président et chef des opérations, et Philippe Adam, chef de la direction financière, tiendront une conférence téléphonique à 8H00 (HE) le jour même pour présenter les résultats de la Société. De plus, l’Assemblée générale annuelle aura également lieu le 13 janvier 2021 à 10H00 (HE). Cette rencontre se tiendra virtuellement sur la plateforme Lumi.Renseignements sur la conférence téléphonique pour présenter les résultats financiers :Quand : Le 13 janvier 2021 à 8H00...

PETAH TIKVA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announces that Bosmat Halpern, Chief Financial Officer and Asaf Jivilik, Head of Marketing and Business Development, will present at the 23rd Annual Needham Growth Conference on Monday, January 11, 2021 at 08:00 a.m. EST.Mrs. Halpern and Mr. Jivilik will also be available for one-on-one meetings during the day of the presentation. To schedule a meeting please contact your Needham salesperson or the Gilat IR team at Gilat@GKIR.comAbout GilatGilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT) is a leading global provider of satellite-based broadband communications. With 30 years of experience, we design and manufacture cutting-edge ground...

                                                                                                           Ress Life Investments A/SHolbergsgade 14, 2 tvDK-1057 Copenhagen KDenmarkCVR nr. 33593163www.resslifeinvestments.comTo: Nasdaq CopenhagenDate: 6 January 2021Corporate Announcement 01/2021Ress Life Investments A/S announces the events of the annual general meetingheld on 6 January 2021.  At the annual general meeting of Ress Life Investments A/S held on Wednesday 6 January 2021, the following decisions were taken:•           The 2019/2020 Annual Report was approved – cf item 1 of the agenda.•           Appropriation of the year’s result was approved – cf item 2 of the agenda.•           Søren Andersen, Jeppe Buskov, Ketil Petersen and Anne Buchardt were re-elected to the Board of Directors – cf item 3 of the agenda.•          ...

ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that it has entered into a securities purchase agreement with institutional investors and certain existing stockholders, providing for the purchase and sale of 4,209,050 shares of common stock at a price of $2.851 per share, priced at-the-market under Nasdaq rules based on the five-day average closing price of the common stock, in a registered direct offering, resulting in total gross proceeds of approximately $12.0 million, before deducting the placement agent’s fees and other estimated offering expenses.The offering is expected to close on or about January 8, 2021,...

– Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 –– Initiation of Phase 1 proof-of-concept study evaluating CRN04894 for the treatment of congenital adrenal hyperplasia and Cushing’s disease expected in January 2021 –– Initiation of Phase 1 proof-of-concept study evaluating CRN04777 for the treatment of congenital hyperinsulinism expected in February 2021 –SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the 39th annual J.P. Morgan Healthcare Conference, which is taking place in a virtual...